MYGN

4.59

2.00% 0.09

Handel nachbörslich: 4.59

Myriad Genetics Inc (MYGN)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MYGN? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$4.50

Offen:

$4.53

24-Stunden-Volumen:

853.94K

Relative Volume:

0.54

Marktkapitalisierung:

$429.20M

Einnahmen:

$824.50M

Nettoeinkommen (Verlust:

$-365.90M

KGV:

-1.1611

EPS:

-3.9531

Netto-Cashflow:

$-25.60M

1W Leistung:

-1.92%

1M Leistung:

-0.43%

6M Leistung:

-40.62%

1J Leistung:

-48.08%

1-Tages-Spanne:

$4.51

$4.695

1-Wochen-Bereich:

$4.20

$4.81

52-Wochen-Spanne:

$3.76

$8.97

Myriad Genetics Inc Stock (MYGN) Company Profile

Firmenname

Myriad Genetics Inc

Sektor

Healthcare (1116)

Branche

Diagnostics & Research (52)

Telefon

801-584-3600

Adresse

322 NORTH 2200 WEST, SALT LAKE CITY, UT

Mitarbeiter

2,700

Twitter

@myriadgenetics

Nächster Verdiensttermin

2025-02-24

Neueste SEC-Einreichungen

MYGN's Discussions on Twitter

Compare MYGN vs TMO, DHR, IDXX, A, WAT

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MYGN Myriad Genetics Inc	4.59	420.79M	824.50M	-365.90M	-25.60M	-3.9531
TMO Thermo Fisher Scientific Inc	494.54	182.60B	44.56B	6.72B	6.29B	17.74
DHR Danaher Corp	190.79	134.18B	24.57B	3.60B	5.26B	5.051
IDXX Idexx Laboratories Inc	564.66	44.63B	4.30B	1.06B	1.04B	13.08
A Agilent Technologies Inc	114.54	32.21B	7.07B	1.29B	993.00M	4.5355
WAT Waters Corp	299.89	29.21B	3.17B	642.63M	516.49M	10.77

Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-05-21	Herabstufung	Scotiabank	Sector Outperform → Sector Perform
2025-05-08	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-05-07	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-04-09	Herabstufung	Guggenheim	Buy → Neutral
2025-03-12	Hochstufung	Piper Sandler	Neutral → Overweight
2025-02-12	Eingeleitet	Craig Hallum	Buy
2024-12-10	Eingeleitet	UBS	Neutral
2024-12-09	Herabstufung	Leerink Partners	Outperform → Market Perform
2024-09-19	Eingeleitet	Morgan Stanley	Equal-Weight
2024-08-28	Eingeleitet	Wells Fargo	Overweight
2024-06-27	Eingeleitet	Scotiabank	Sector Outperform
2024-06-03	Fortgesetzt	Jefferies	Underperform
2024-05-08	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-12-21	Fortgesetzt	Piper Sandler	Neutral
2023-12-19	Eingeleitet	Wells Fargo	Equal Weight
2023-12-14	Eingeleitet	Guggenheim	Buy
2023-12-13	Eingeleitet	Wolfe Research	Outperform
2023-07-05	Fortgesetzt	JP Morgan	Underweight
2023-05-23	Hochstufung	Goldman	Sell → Buy
2023-01-18	Hochstufung	Raymond James	Mkt Perform → Outperform
2022-10-06	Eingeleitet	Stephens	Equal-Weight
2021-10-15	Fortgesetzt	Cowen	Market Perform
2021-06-15	Eingeleitet	Raymond James	Mkt Perform
2021-06-03	Eingeleitet	Goldman	Sell
2019-09-26	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-08-14	Herabstufung	Piper Jaffray	Overweight → Neutral
2019-08-02	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-08-01	Hochstufung	Barclays	Underweight → Equal Weight
2019-07-29	Herabstufung	Needham	Strong Buy → Hold
2019-07-09	Herabstufung	Cowen	Outperform → Market Perform
2019-03-12	Bestätigt	Needham	Strong Buy
2019-01-03	Eingeleitet	Needham	Strong Buy
2018-11-30	Hochstufung	Goldman	Sell → Neutral
2018-10-10	Hochstufung	Piper Jaffray	Neutral → Overweight
2018-07-11	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2018-03-21	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2018-01-29	Eingeleitet	Goldman	Sell
2018-01-22	Bestätigt	Barclays	Equal Weight
2018-01-05	Eingeleitet	BTIG Research	Buy
2017-10-02	Fortgesetzt	Leerink Partners	Mkt Perform
2017-08-09	Bestätigt	Barclays	Equal Weight
2017-02-08	Hochstufung	Ladenburg Thalmann	Sell → Neutral
2017-01-18	Eingeleitet	Deutsche Bank	Sell
2016-10-10	Herabstufung	Ladenburg Thalmann	Neutral → Sell

Alle ansehen

Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten

Mar 31, 2026

Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know - Yahoo Finance

Mar 27, 2026

Vanguard (MYGN) amendment shows 0 shares; subsidiaries disaggregate holdings - Stock Titan

Mar 27, 2026

Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Mar 27, 2026

Mar 26, 2026

MYGN Stock Price, Quote & Chart | MYRIAD GENETICS INC (NASDAQ:MYGN) - chartmill.com

Mar 26, 2026

Mar 25, 2026

Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 25, 2026

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - natlawreview.com

Mar 25, 2026

Mar 24, 2026

Myriad Genetics launches Prequel Prenatal Screen using AMPLIFY technology for early chromosomal risk detection - Traders Union

Mar 24, 2026

Mar 23, 2026

Myriad Genetics (MYGN) CSO has shares withheld to cover RSU taxes - Stock Titan

Mar 23, 2026

Myriad Genetics (MYGN) COO has 2,055 shares withheld to cover taxes - Stock Titan

Mar 23, 2026

Myriad Genetics (MYGN) CFO uses 549 shares for RSU tax withholding - Stock Titan

Mar 23, 2026

Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript - GuruFocus

Mar 23, 2026

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 - marketscreener.com

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P Composite 1500 - marketscreener.com

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 600 Health Care - marketscreener.com

Mar 22, 2026

Myriad Genetics, Inc.(NasdaqGS: MYGN) dropped from S&P 1000 - marketscreener.com

Mar 22, 2026

Mar 21, 2026

If You Invested $1,000 in Myriad Genetics (MYGN) - Stock Titan

Mar 21, 2026

Gene Patent Showdown For Myriad Comes to a Head - Yahoo

Mar 21, 2026

MYGN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Mar 21, 2026

Mar 19, 2026

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term - Yahoo Finance

Mar 19, 2026

Mar 18, 2026

Prequel Prenatal Screen enables providers to act on uncertain results, Myriad Genetics asserts - Traders Union

Mar 18, 2026

Why Myriad Genetics (MYGN) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Mar 18, 2026

Myriad Genetics (MYGN) Q4 earnings and revenues surpass estimates - MSN

Mar 18, 2026

Myriad Genetics receives FDA approval for ovarian cancer test By Investing.com - za.investing.com

Mar 18, 2026

Mar 17, 2026

FDA Approves Myriad Genetics' MyChoice CDx Test for Advanced Ova - gurufocus.com

Mar 17, 2026

Myriad Genetics receives FDA approval for ovarian cancer test - Investing.com

Mar 17, 2026

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - The Manila Times

Mar 17, 2026

Portfolio Update: Can Myriad Genetics Inc maintain its current growth rate2026 Trading Volume Trends & Community Driven Trade Alerts - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Myriad Genetics (MYGN) CTO has shares withheld to cover taxes - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CFO granted 206,186 RSUs, 4,752 shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) grants 173196 RSUs, withholds 14683 shares for tax - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CSO gets 173,196 RSUs, withholds 37,799 shares - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CLO granted 195,876 RSUs and has shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) Chief Commercial Officer granted 226,804 RSUs - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) COO receives RSU grant, shares withheld for tax - Stock Titan

Mar 16, 2026

Myriad Genetics (MYGN) CEO gets 618,557 RSUs, 47,120 shares withheld - Stock Titan

Mar 16, 2026

Myriad Genetics Inc Stock (ISIN: US62855J1043) Eyes Precision Medicine Growth Amid Margin Expansion - AD HOC NEWS

Mar 16, 2026

Mar 15, 2026